$ACON

Aclarion, Inc.

Aclarion is a healthcare technology company that uses magnetic resonance spectroscopy (MRS), proprietary biomarkers and software to help clinicians assess pain in spinal discs and inform treatment decisions. Its initial focus is chronic discogenic low back pain, particularly surgical planning. The company’s NOCISCAN platform analyzes MRS data from compatible MRI scanners and sends clinicians a report identifying discs as painful or not. The platform includes NOCICALC, which processes spectroscopy data and calculates biomarkers, and NOCIGRAM, which presents the results in a diagnostic report. Aclarion also provides a data-transfer platform for sending exam data to its cloud-based processing system. Aclarion makes money by marketing and selling its NOCISCAN post-processor software products. Its technology is compatible with certain SIEMENS and PHILIPS scanner models. Aclarion is headquartered in Broomfield, Colorado.

No enriched coverage for $ACON in the last 7 days.

$5K
—
Gould Gregory A
0%
See all $ACON insider activity →

Aclarion Updates CLARITY Enrollment Criteria, Keeps Trial Timeline On Track

Aclarion (ACON) revised its CLARITY trial enrollment criteria to expand the patient pool and accelerate enrollment, while maintaining scientific rigor. The changes were approved by most trial sites and are expected to improve enrollment consistency and real-world applicability. The company anticipates providing an enrollment update by year-end 2026, with the trial timeline remaining unchanged. ACON's stock closed at $2.35, up 2.40%.

ACON sentiment & insider activity

Recent ACON coverage spans insider activity, financial news and technology.

In the last 30 days, ACON insiders filed 1 SEC Form 4 transaction — 1 purchase ($5K) and no sales. The most active reporter was Gould Gregory A, CFO, with 1 filing.

What's driving ACON

  • Small insider purchase may create modest buying pressure.

    SEC EDGAR · Nov 20, 2026

  • The enrollment change is expected to increase patient flow and may improve trial timelines, supporting the stock.

    rttnews.com · Oct 8, 2026

  • Small insider buy may signal confidence but limited market impact due to modest size.

    SEC EDGAR · Aug 19, 2026

  • This is an insider open-market buy by the CFO, which can be read as mild positive sentiment but is not a fundamental catalyst by itself.

    SEC EDGAR · Aug 18, 2026

  • This is a director open-market buy disclosed via Form 4, which can be mildly supportive for sentiment but is not a fundamental catalyst by itself.

    SEC EDGAR · Aug 17, 2026

AlphAI scores every news story that mentions ACON with an AI model for sentiment and relevance, and aggregates insider trades from Aclarion, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ACON

Score
$ACONMedAI 8/10

Aclarion Updates CLARITY Enrollment Criteria, Keeps Trial Timeline On Track

Aclarion (ACON) revised its CLARITY trial enrollment criteria to expand the patient pool and accelerate enrollment, while maintaining scientific rigor. The changes were approved by most trial sites and are expected to improve enrollment consistency and real-world applicability. The company anticipates providing an enrollment update by year-end 2026, with the trial timeline remaining unchanged. ACON's stock closed at $2.35, up 2.40%.

Aclarion, Inc.: Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion, Inc. (Nasdaq: ACON) said the USPTO issued a Notice of Allowance for a patent application covering “Multi-Voxel Prescription for Lumbar Disc Evaluation,” aimed at improving MR spectroscopy voxel positioning in its Nociscan workflow. The company said the claims are intended to reduce repeat scans and variability across sites, extending its IP portfolio of 65+ patents worldwide.

Related tickers